Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Sangamo Therapeutics's operating income for the twelve months ending Mar 31, 2026 was -$123.56M. For fiscal 2025 it was -$121.24M. The highest annual figure on record is -$19.40M in fiscal 2009.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$121.24M | – |
| FY2024 | Dec 31, 2024 | -$103.97M | – |
| FY2023 | Dec 31, 2023 | -$274.01M | – |
| FY2022 | Dec 31, 2022 | -$201.28M | – |
| FY2021 | Dec 31, 2021 | -$183.34M | – |
| FY2020 | Dec 31, 2020 | -$129.55M | – |
| FY2019 | Dec 31, 2019 | -$105.18M | – |
| FY2018 | Dec 31, 2018 | -$77.15M | – |
| FY2017 | Dec 31, 2017 | -$56.36M | – |
| FY2016 | Dec 31, 2016 | -$72.56M | – |
| FY2015 | Dec 31, 2015 | -$46.86M | – |
| FY2014 | Dec 31, 2014 | -$26.78M | – |
| FY2013 | Dec 31, 2013 | -$26.71M | – |
| FY2012 | Dec 31, 2012 | -$22.20M | – |
| FY2011 | Dec 31, 2011 | -$35.82M | – |
| FY2010 | Dec 31, 2010 | -$24.94M | – |
| FY2009 | Dec 31, 2009 | -$19.40M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$31.95M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$35.55M | -434.4% |
| Q2 FY2025 | Jun 30, 2025 | -$17.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.63M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.99M | – |
| Q3 FY2024 | Sep 30, 2024 | $10.63M | – |
| Q2 FY2024 | Jun 30, 2024 | -$37.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$51.53M | -385.7% |
| Q4 FY2023 | Dec 31, 2023 | -$62.06M | – |
| Q3 FY2023 | Sep 30, 2023 | -$106.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -$123.57M | – |
| Q1 FY2023 | Mar 31, 2023 | $18.03M | – |
| Q4 FY2022 | Dec 31, 2022 | -$55.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$54.89M | – |
| Q2 FY2022 | Jun 30, 2022 | -$45.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$45.26M | – |
| Q4 FY2021 | Dec 31, 2021 | -$39.90M | – |
| Q3 FY2021 | Sep 30, 2021 | -$48.44M | – |
| Q2 FY2021 | Jun 30, 2021 | -$48.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$46.30M | – |
| Q4 FY2020 | Dec 31, 2020 | -$43.43M | -3056.6% |
| Q3 FY2020 | Sep 30, 2020 | -$3.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$37.90M | – |
| Q1 FY2020 | Mar 31, 2020 | -$44.52M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.47M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.25M | – |
| Q2 FY2019 | Jun 30, 2019 | -$33.50M | – |
| Q1 FY2019 | Mar 31, 2019 | -$43.90M | – |
| Q4 FY2018 | Dec 31, 2018 | -$20.77M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.24M | – |
| Q2 FY2018 | Jun 30, 2018 | -$19.14M | – |
| Q1 FY2018 | Mar 31, 2018 | -$21.00M | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.77M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.04M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.77M | – |
| Q1 FY2017 | Mar 31, 2017 | -$16.79M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.83M | – |
| Q3 FY2016 | Sep 30, 2016 | -$19.21M | – |
| Q2 FY2016 | Jun 30, 2016 | -$26.84M | – |
See a number that looks wrong?